Which sequence correctly lists the steps for the Rx-to-OTC switch pathways known as SPAM?

Which sequence correctly lists the steps for the Rx-to-OTC switch pathways known as SPAM?

• A. Supplemental NDA → Petition FDA → Amend drug Monograph
• B. Petition FDA → Supplemental NDA → Amend drug Monograph
• C. Amend drug Monograph → Submit Supplemental NDA → Petition FDA
• D. Submit Supplemental NDA → Amend drug Monograph → Petition FDA

Answer: (A)

The sequence tests how an Rx-to-OTC switch is finalized through the SPAM pathway, which links a product-level change to the formal OTC framework. SPAM stands for Supplemental NDA, Petition FDA, Amend drug Monograph. Start with a supplemental NDA to request the switch for the specific product, kicking off FDA’s product-specific safety, labeling, and use review for OTC eligibility. After that review, you file a petition with FDA to update the OTC monograph framework to accommodate the new status and any conditions attached to the switch. Once that petition is considered and approved, you complete the process by amending the drug monograph to codify the new OTC status, labeling, dosing instructions, and indications for the product within the monograph record. This order makes sense because it begins with a product-specific regulatory decision, then aligns the broader monograph framework, and finally records the change in the official monograph.

The sequence tests how an Rx-to-OTC switch is finalized through the SPAM pathway, which links a product-level change to the formal OTC framework. SPAM stands for Supplemental NDA, Petition FDA, Amend drug Monograph. Start with a supplemental NDA to request the switch for the specific product, kicking off FDA’s product-specific safety, labeling, and use review for OTC eligibility. After that review, you file a petition with FDA to update the OTC monograph framework to accommodate the new status and any conditions attached to the switch. Once that petition is considered and approved, you complete the process by amending the drug monograph to codify the new OTC status, labeling, dosing instructions, and indications for the product within the monograph record. This order makes sense because it begins with a product-specific regulatory decision, then aligns the broader monograph framework, and finally records the change in the official monograph.